## Oscar Segurado

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8614570/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Annals of the Rheumatic Diseases, 2006, 65, 753-759.	0.9	184
2	Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis and Rheumatism, 2009, 60, 1242-1249.	6.7	127
3	Clinical Assessment of Pain, Tolerability, and Preference of an Autoinjection Pen Versus a Prefilled Syringe for Patient Self-Administration of the Fully Human, Monoclonal Antibody Adalimumab: The TOUCH Trial. Clinical Therapeutics, 2006, 28, 1619-1629.	2.5	110
4	Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Annals of the Rheumatic Diseases, 2006, 65, 820-822.	0.9	85
5	Expression and function of a variant T cell receptor complex lacking CD3-gamma Journal of Experimental Medicine, 1991, 174, 319-326.	8.5	68
6	Comparison between HLA-DRB and DQ DNA sequences and classic serological markers as Type 11 (insulin-dependent)diabetes mellitus predictive risk markers in the Spanish population. Diabetologia, 1992, 35, 475-481.	6.3	45
7	HUMIRA®Pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab. Expert Review of Medical Devices, 2007, 4, 109-116.	2.8	44
8	Clinical significance of serum and CSF findings in the Guillain-Barrï;½ syndrome and related disorders. Journal of Neurology, 1986, 233, 202-208.	3.6	41
9	Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 16-26.	2.0	38
10	Prospective clinical study of circulating tumor cells for colorectal cancer screening Journal of Clinical Oncology, 2018, 36, 556-556.	1.6	31
11	Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. Rheumatology, 2016, 55, 640-648.	1.9	29
12	Selective concentration of anti-Purkinje cell antibody in the CSF of two patients with paraneoplastic cerebellar degeneration. Acta Neurologica Scandinavica, 1988, 78, 210-213.	2.1	28
13	Both HLA class II and class III DNA polymorphisms are linked to juvenile rheumatoid arthritis susceptibility. Clinical Immunology and Immunopathology, 1990, 56, 22-28.	2.0	22
14	Two BF F Subtypes, but no BF S, BF F1 or BF S07 Subdivision, Are Found by Isoelectric Focusing. Vox Sanguinis, 1989, 56, 117-121.	1.5	14
15	Autoimmunogenic HLA-DRB1â^—0301 allele (DR3) may be distinguished at the DRB1 non-coding regions of HLA-B8,DR3,Dw24 and B18,DR3,Dw25 haplotypes. Molecular Immunology, 1991, 28, 189-192.	2.2	12
16	C4 Chido 3 and 6 Distinguish Two Diabetogenic Haplotypes: HLA-B49,SC01,DR4,DQw8 and B8,SC01,DR3,DQw2. Immunobiology, 1991, 183, 12-22.	1.9	10
17	The Multifactorial Nature of MHC-Linked Susceptibility to Insulin-Dependent Diabetes. Autoimmunity, 1993, 15, 85-89.	2.6	8
18	Identification of predominant T-cell receptor rearrangements by temperature-gradient gel electrophoresis and automated DNA sequencing. Electrophoresis, 1993, 14, 747-752.	2.4	7

OSCAR SEGURADO

#	Article	IF	CITATIONS
19	New DNA sequences for the human complement gene C4. Molecular Immunology, 1993, 30, 515-516.	2.2	7
20	A novel diabetesâ€susceptibility HLA haplotype is present in the Croatian population. Tissue Antigens, 1993, 41, 107-109.	1.0	5
21	A novel circulating tumor cell blood test for early detection of colorectal, prostate, and breast cancers: Results from 709 samples Journal of Clinical Oncology, 2018, 36, e13549-e13549.	1.6	4
22	Shared Sstl RFLPs by HLAâ€Aw19, A23/24 and A3/11 crossreacting groups. Tissue Antigens, 1990, 35, 206-210.	1.0	3
23	Factor B activation in systemic lupus erythematosus. Arthritis and Rheumatism, 1990, 33, 1598-1599.	6.7	3
24	Prospective clinical study of a prostate cancer (PCa) rule-out blood test for PSA gray zone patients using a sensitive circulating tumor cell assay Journal of Clinical Oncology, 2018, 36, 143-143.	1.6	3
25	Restricted TCR repertoire and disease. Trends in Immunology, 1993, 14, 45.	7.5	2
26	Acquired selective signature dysgraphia. Annals of Neurology, 1992, 31, 115-115.	5.3	1
27	The CSF IgG from patients with Guillain-Barré syndrome. Acta Neurologica Scandinavica, 1987, 75, 283-283.	2.1	Ο
28	Genome ethics treaty. Nature, 1991, 352, 368-368.	27.8	0
29	Running out of steam …. Nature, 1992, 360, 502-503.	27.8	0
30	Spanish laboratory backs off bid to cut research staff. Nature, 1993, 366, 8-8.	27.8	0
31	Spain expands despite financial and logistical hurdles. Nature, 1993, 362, 578-578.	27.8	0
32	New DNA sequences for the human complement gene C4. Human Immunology, 1993, 36, 47.	2.4	0
33	Abstract 3652: Analytical validation of a novel circulating tumor DNA detection platform for targeted and immunotherapy selection. , 2018, , .		0
34	Abstract 2241: Comparison of rare pathogenic germline variants associated with cancer predisposition syndrome in Taiwan and USA populations. , 2018, , .		0